ArticleIJID regions2025
Clinical presentation of Enterovirus D68 in adults with acute respiratory infections consulting in emergency departments in Quebec, Canada.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- National Surveillance of Enterovirus D68 Upsurge, France, 2024.Emerging infectious diseases · 2026Article
- Enterovirus respiratory infection in adults: an overlooked clinical burden emerging in the post-pandemic era.Le infezioni in medicina · 2026Article
- Enterovirus D68 and mycobacterial coinfection: case report.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Enterovirus D68 (EV-D68) is mainly studied in children, while data in adults are limited. We described the clinical presentation of EV-D68 in adults, compared with other enterovirus/rhinovirus (EV/RV) infections. Methods: We used clinical and laboratory data from 1143 adults visiting four emergency departments in Quebec, Canada, for acute respiratory infections (February 2022 to March 2023). We analyzed nasopharyngeal swabs using a multiplex polymerase chain reaction; positive EV/RV samples were further tested with EV-D68-specific polymerase chain reaction assays. We calculated the Pandemic Medical Early Warning Score (PMEWS) to assess severity. Results: Of 155 (14%) EV/RV samples, 19 (12%) were EV-D68 and occurred from July to October, 2022. Patients with EV-D68 more frequently lived with other people (100% vs 73%, Conclusions: Respiratory symptoms tended to be more common among participants with EV-D68 than those with other EV/RV, although disease severity was similar. Larger studies are needed to better characterize EV-D68 infections in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.